Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... -- BerGenBio AS, a biopharmaceutical company focused ... today announces that it has raised NOK90 million (c. ... existing investors. BerGenBio will use the proceeds ... pipeline of innovative cancer therapeutics, in particular an enlarged ... a first-in-class selective Axl kinase inhibitor, which is currently ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014   ... SAN and NYSE: SNY) are collaborating with nationally-recognized patient ... Counts , an awareness program that will gauge how ... risks associated with high LDL-C (bad cholesterol).  American adults ... to take a brief poll and answer a few ...
(Date:12/15/2014)... Dec. 15, 2014 As medical device manufacturers ... Labeling) markup language standard, content teams have a greater ... to work with the standard. Starting January 2015, Data ... webinars on the benefits and the critical aspects of ... be facilitated by Howard Shatz , DCL,s SPL ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3
... HOPKINTON, Mass., Nov. 3, 2010 ... ), a leading provider of tools and services ... announced a collaboration with Sony DADC Austria AG ... for Caliper,s next generation microfluidics products. The agreement ...
... Whether it,s reducing infections for patients, increasing the number ... hospitals to develop a philosophy and culture of quality, ... help save lives and health care dollars. ... and physician P4P program demonstrates a number of positive ...
Cached Medicine Technology:Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2Highmark's Collaboration With Hospitals and Doctors Continues to Yield Benefits for all Patients 2Highmark's Collaboration With Hospitals and Doctors Continues to Yield Benefits for all Patients 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... member can be stressful and can pose health threats to ... Development and Family Studies, Penn State, received a $3 million ... effects of caregiving on familial caregivers. He will look at ... adult day care impacts the stress levels of all individuals ...
... halo surrounding highly-publicized marketing campaigns regarding sweetener reformulations is ... Starbucks and other brands that they will remove high ... into question in news articles by several experts and ... companies, marketing efforts and put forth scientifically substantiated facts ...
... June 30 MicroMass Communications, Inc., a leader in ... appointed veteran business executive and marketing strategist Richard Patterson ... He will spearhead the agency,s oncology business, reporting to ... , , Patterson brings almost three decades ...
... June 30 Delaware,s Partnership to Fight Chronic Disease (PFCD), ... a major part of comprehensive health reform, hosted a breakfast ... for chronic disease management and care. , ... every year and 75 percent - or $1.7 trillion - ...
... NDA - AllerNaze(TM) , , BSE: 500257 NSE: ... , MUMBAI, India, June 30 Pharmaceutical Major, Lupin Ltd. ... steroid (INS) product, AllerNaze(TM) (triamcinolone acetonide, USP) Nasal Spray, 50mcg ... will be the first market in which Lupin will launch ...
... women who feel sensitive to rejection based on their physical ... surgery than those who are less sensitive to appearance-based rejection. ... comments about their physical appearance. The ... Body Image , was conducted by Lora E. Park, ...
Cached Medicine News:Health News:Caregivers may benefit from adult day care 2Health News:Recent News Reports of Sweetener Reformulations Raise Questions About Motivations 2Health News:Recent News Reports of Sweetener Reformulations Raise Questions About Motivations 3Health News:MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP, Group Account Director 2Health News:MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP, Group Account Director 3Health News:Delaware's Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spending and Improved Patient Health 2Health News:Lupin Expands Branded Play 2Health News:Lupin Expands Branded Play 3Health News:Cosmetic surgery appeals to men, women with appearance-based rejection sensitivity 2
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: